The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Systemic Activation of the Transient Receptor Potential Vanilloid Subtype 4 Channel Causes Endothelial Failure and Circulatory Collapse: Part 2
Abstract
The transient receptor potential (TRP) vanilloid subtype 4 (V4) is a nonselective cation channel that exhibits polymodal activation and is expressed in the endothelium, where it contributes to intracellular Ca2+ homeostasis and regulation of cell volume. The purpose of the present study was to evaluate the systemic cardiovascular effects of GSK1016790A, a novel TRPV4 activator, and to examine its mechanism of action. In three species (mouse, rat, and dog), the i.v. administration of GSK1016790A induced a dose-dependent reduction in blood pressure, followed by profound circulatory collapse. In contrast, GSK1016790A had no acute cardiovascular effects in the TRPV4-/- null mouse. Hemodynamic analyses in the dog and rat demonstrate a profound reduction in cardiac output. However, GSK1016790A had no effect on rate or contractility in the isolated, buffer-perfused rat heart, and it produced potent endothelial-dependent relaxation of rodent-isolated vascular ring segments that were abolished by nitric-oxide synthase (NOS) inhibition (N-nitro-L-arginine methyl ester; L-NAME), ruthenium red, and endothelial NOS (eNOS) gene deletion. However, the in vivo circulatory collapse was not altered by NOS inhibition (L-NAME) or eNOS gene deletion but was associated with (concentration and time appropriate) profound vascular leakage and tissue hemorrhage in the lung, intestine, and kidney. TRPV4 immunoreactivity was localized in the endothelium and epithelium in the affected organs. GSK1016790A potently induced rapid electrophysiological and morphological changes (retraction/condensation) in cultured endothelial cells. In summary, inappropriate activation of TRPV4 produces acute circulatory collapse associated with endothelial activation/injury and failure of the pulmonary microvascular permeability barrier. It will be important to determine the role of TRPV4 in disorders associated with edema and microvascular congestion.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HUVECs may not entirely recapitulate all known roles for TRPV4 in tumor vasculature. 24,28,35,51,53,66”
From Rapid Assessment of Nanoparticle Extravasation in a Microfluidic Tumor Model (2019) · cites this paper as [24]
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
Liedtke, W., Choe, Y., Martı́-Renom, M. A., Bell, A. M., Denis, C. S., AndrejŠali, Hudspeth, A. J., Friedman, J. M., & Heller, S. (2000) · Cell · doi:10.1016/s0092-8674(00)00143-4 · Cited by 1,391
Cellular regulation of endothelial nitric oxide synthase
Govers, R., & Rabelink, T. J. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.280.2.f193 · Cited by 476
TRPV4 Forms a Novel Ca 2+ Signaling Complex With Ryanodine Receptors and BK Ca Channels
Earley, S., Heppner, T. J., Nelson, M. T., & Brayden, J. E. (2005) · Circulation Research · doi:10.1161/01.res.0000194321.60300.d6 · Cited by 448
Yue, T., Wang, C., Gu, J.-L., Ma, X., Kumar, S., Lee, J. C., Feuerstein, G., Thomas, H. C., Maleeff, B. E., & Ohlstein, E. H. (2000) · Circulation Research · doi:10.1161/01.res.86.6.692 · Cited by 421
Self-citationTransient Receptor Potential Channels in Cardiovascular Function and Disease
Inoue, R., Jensen, L. J., Shi, J., Morita, H., Nishida, M., Honda, A., & Ito, Y. (2006) · Circulation Research · doi:10.1161/01.res.0000233356.10630.8a · Cited by 368
Köhler, R., Heyken, W., Heinau, P., Schubert, R., Si, H., Kacik, M., Busch, C., Grgic, I., Maier, T., & Hoyer, J. D. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000225698.36212.6a · Cited by 346
Transient Receptor Potential Vanilloid 4–Mediated Disruption of the Alveolar Septal Barrier
Alvarez, D. F., KING, J. A. C., Weber, D. S., Addison, E., Liedtke, W., & Townsley, M. I. (2006) · Circulation Research · doi:10.1161/01.res.0000247065.11756.19 · Cited by 311
Yang, X.-R., Lin, M., McIntosh, L. S., & Sham, J. S. K. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00515.2005 · Cited by 278
Self-citationRecent Developments in Vascular Endothelial Cell Transient Receptor Potential Channels
Yao, X., & Garland, C. J. (2005) · Circulation Research · doi:10.1161/01.res.0000187473.85419.3e · Cited by 276
Cited by
Sorted by citations
Items 301–307 of 307
BindingDB Entry 50011116: Recent advances in TRPV4 agonists and antagonists.
BindingDB (2021) · UC San Diego · doi:10.7270/q29g5rc5
BindingDB (2016) · UC San Diego · doi:10.7270/q2pg1thp
BindingDB (2021) · UC San Diego · doi:10.7270/q2kk9g6n
Metadata
- Authors
- Willette, R. N., Bao, W., Nerurkar, S., Yue, T.-L., Doe, C. P., Stankus, G., Turner, G. H., Ju, H., Thomas, H., Fishman, C. E., Sulpizio, A., Behm, D. J., Hoffman, S., Lin, Z., Lozinskaya, I., Casillas, L. N., Lin, M., Lee Trout, R. E., Votta, B. J., Thorneloe, K., Lashinger, E. S. R., Figueroa, D. J., Marquis, R., & Xu, X.
- Affiliations
- GlaxoSmithKline (United States) (US)
- ORCID
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2008-08
- Volume
- 326
- Issue
- 2
- Pages
- 443-452
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2161804336
- Cited by
- 300
- References
- 21
- Citations by year
- 2026: 12 · 2025: 8 · 2024: 8 · 2023: 20 · 2022: 16 · 2021: 14 · 2020: 24 · 2019: 21 · 2018: 16 · 2017: 22 · 2016: 17 · 2015: 19 · 2014: 22 · 2013: 14 · 2012: 20
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Update notices
- erratum (2011-07-01)
- Open access
- closed
- Locations
- Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Calcium signaling and nucleotide metabolism
- Keywords
- TRPV4, GSK1016790A, cardiovascular collapse, endothelial permeability, endothelial injury, endothelial cell retraction, nitric oxide synthase, endothelium-dependent relaxation, blood pressure reduction, cardiac output, TRPV4 knockout mice, edema
- MeSH terms
- Animals, Aorta, Thoracic, Capillary Permeability, Cell Adhesion, Cell Line, Dogs, Dose-Response Relationship, Drug, Endothelium, Vascular, Female, Hemodynamics, Humans, Immunohistochemistry, Leucine, Male, Sulfonamides, Vasoconstriction, Molecular Structure, Ventricular Function, Left, Rats, Sprague-Dawley, Mice, Knockout, Patch-Clamp Techniques, TRPV Cation Channels, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review